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as the number of patients still in the trial and free of any " major cardiac event," expressed as a percentage of the total number in the trial at that point-that is, the number of starters less those removed for non-cardiac complications or lost to follow-up.
At two years the proportion of patients remaining free of major cardiac events is greater for the control group (75%) than for the two oil groups (olive oil 57%, corn oil 52%). The likelihood that the difference between the control and corn-oil groups was due to chance is 0.05-0.1 (S.E. of difference, + 13 %). Among those patients who were followed for a third year no new trend emerged.
Conclusion
The aim of the trial was not to duplicate the many carefully regulated laboratory studies of the effects of unsaturated oils on serum cholesterol. Rather was it aimed to study the feasibility and possible value of such regimes in a typical group of hospital coronary patients. Among such persons, and especially where treatment is prolonged, it is inevitable that some will comply incompletely or not at all. We estimated that initially the patients in the two oil groups took on average about 90% of the prescribed 80 g./day; but after a year the estimated average intake fell to around 60% of the ideal. As a result the differences in serum-cholesterol levels between the two oil groups are less than would be predicted theoretically, although still highly significant. Such limitations may be unavoidable in a clinical trial of a rather unpleasant regime.
The patients receiving the key treatment (corn oil) fared worse than those in the other two groups: two years from the start of treatment infarction or death had occurred in onequarter more of the corn-oil than of the control group. This difference closely approaches the conventional significance level (0.1>P>0.05). The probability that a true difference of the same magnitude but in the other direction may have been missed by chance is less than 1 in 1,000. It is concluded that under the circumstances of this trial corn oil cannot be recommended as a treatment of ischaemic heart disease. It is most unlikely to be beneficial, and it is possibly harmful.
Summary
Eighty patients with ischaemic heart disease were allocated randomly to three treatment groups. The first was a control group. The second received a supplement of olive oil with restriction of animal fat. The third received corn oil with restriction of animal fat. The serum-cholesterol levels fell in the corn-oil group, but by the end of two years the proportions of patients remaining alive and free of reinfarction (fatal or non-fatal) were 75 %, 57 %, and 52 % in the three groups respectively. The likelihood that the worse experience of the patients treated with corn oil was due to chance alone was 0.05-0.1. The likelihood that the trial failed by chance to detect a true and important benefit from corn oil was extremely remote. It is concluded that under the circumstances of this trial corn oil cannot be recommended in the treatment of ischaemic heart disease.
The remarkable potential of carcinomas of the bronchus to produce endocrine disorders, such as Cushing's syndrome (Brown, 1928), hyponatraemia (Winkler and Crankshaw, 1938) , gynaecomastia (Hardy, 1960) , and hypercalcaemia (Connor et al., 1956) , is now well recognized. The most recent addition to this group of disorders is the carcinoid syndrome, and this is known to be associated with 5-hydroxytryptamine (5-H.T.) secretion (Williams and Azzopardi, 1960) and also with 5-hydroxytryptophan (5-H.T.P.) secretion (Gowenlock et al., 1964) . However, 5-H.T. and its metabolites are probably not the direct mediators of carcinoid flushes, and the release of a kinin peptide from the tumour has recently been suggested as responsible (Oates et al., 1964) .
We recently had the opportunity to study 5-H.T. metabolism and kinins in a patient with many features of the carcinoid syndrome who was ultimately shown to have an oat-cell carcinoma of the bronchus. As this association has only rarely been recognized and our ignorance of the mechanism responsible for the flushing in the carcinoid syndrome continues, it was thought that our investigations of a single patient would be of sufficient interest to justify a case report.
Case Report A bus-conductor aged 43 was admitted to hospital with a history of upper abdominal discomfort, nausea, anorexia, and loss of weight for the previous three months; during the month preceding admis- (1962) and by Gaddum and Horton (1959) .
Results
The results of the estimation of indolic compounds in the urine and the response to treatment are summarized in the The only biochemical alteration demonstrated with treatment was a fall in the urinary 5-H.T. excretion on the administration of chlorpromazine. The apparent fall in the 5-H.I.A.A. is an artifact due to interference with the colour reaction by chlorpromazine.
The kinin content of venous whole blood before drug therapy was 25 mplg./ml. equivalent of standard bradykinin (normal less than 0.4 mag./ml.). The P.C.V. was 42%, making the kinin content of the plasma 43.1 mitg./ml. equivalent of bradykinin (normal less than 0.7 mig./ml.). Control experiments showed that the activity measured was bradykinin-like and could not have been due to 5-H.T.
or histamine or substance P as has been suggested (Lancet, 1964) .
Biochemical Investigations
Methods.-Ten 24-hour urine collections were made before and during treatment and the indolic compounds were determined in aliquots. 5-Hydroxyindole acetic acid (5-H.I.A.A.) was determined by the method of Udenfriend et al. (1955) Although its exact mode of action is unknown, chlorpromazine is said to reduce 5-H.T. turnover in the brain (Gey and Pletscher, 1962) , but this may be due to the hypothermia induced (Bartlet, Carcinoma of Bronchus-Kinloch et al. MBA1U 1535 MBA1U 1965 ). An anti-bradykinin effect is also described (Spector and Willoughby, 1963a) (Doepfner and Cerletti, 1958) , showed no effect clinically or chemically.
Oates et al. (1964) have shown that bradykinin, a kinin peptide formed by the proteolytic action of kallikrein on plasma a2-globulin, could induce the characteristic flush in carcinoid patients. Trasylol, an inhibitor of kallikrein and other proteolytic enzymes, was discovered by Frey et al. (1950) . It was used by Frey (1953-4) in the treatment of acute pancreatitis on account of its trypsin-inactivating effect, and has been used extensively since then with promising results (Maurer, 1961 Homochlorcyclizine, which has been shown to have an antihistamine and antiserotonin action, and inhibits slow release substance in animals (Kimura et al., 1960) , had no clinical effect; nor had aspirin, which also has an inhibitory effect on kinins and slow release substance in animals (Collier, 1963 ; Spector and Willoughby, 1963b) .
Discussion
The facial flush, oedema, and hyperperistalsis together suggested the diagnosis of the carcinoid syndrome, and this was confirmed by the raised blood levels of 5-H.T. and kinins, and the increased urinary excretion of 5-H.T. and 5-H.I.A.A. Radiological examination of the chest suggested that the primary tumour might be in the lung, and at necropsy an oat-cell carcinoma was found in the right upper lobe apical bronchus, and this was thought to be the primary lesion; there were multiple secondary deposits in the liver. 5-H.T. was found in small amounts in the liver metastases only.
Despite the presence of tumour tissue in the liver containing 5-H.T. and the relatively high blood levels of 5-H.T., there were no fibrotic lesions in the heart or other organs, as have been described in the carcinoid syndrome, and which have recently been reviewed by Halkn (1964) . It may be that the rapid downhill course of this patient did not permit time for the deposition of the characteristic fibrous plaques on the heart and great vessels.
The hypokalaemia noted, together with the hyperplasia of the adrenal cortex, suggested the possibility that the tumour was producing a substance with corticotrophin-like activity, as described by Holub and Katz (1961) and by Meador et al. (1962) . Apart from the facies and hypokalaemia, however, there are no grounds for postulating persistent adrenocortical overactivity.
Treatment with a series of drugs had no clinical effect and only slight biochemical changes were noted with one drug, chlorpromazine; no attempt was made to detect alterations in blood kinin levels. It must be concluded that 5-H.T. and kinin antagonists in the dosage given were of no value in this patient, and their administration did not throw further light on the cause of the carcinoid flush, as might have been hoped.
Smmary
The case of a patient with the carcinoid syndrome is described in which there was an associated oat-cell carcinoma of the bronchus.
Antagonists to 5-H.T. and kinin peptides were administered with no demonstrable effect, except some subjective improvement and a slight fall in the 5-H.T. urinary excretion during chlorpromazine administration.
